Faron, etusivu

releases and publications

Holding(s) in Company

Shareholder announcement Regulatory

Registration of New Shares

Regulatory

Announcement of Placing

Regulatory

Faron notice of EGM

Regulatory

Faron Announces Top-Line 12-Month Survival Results

Regulatory

First Patient Dosed in Ph I/II BEXMAB Combo Study

Exercise of options

Regulatory

Presentation of Biomarker Analysis at ASCO

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies

Regulatory

Ex Vivo Data Presented at EHA2022 Congress

PreviousNext
Back to top